AstraZeneca sales and marketing update

The U.K.’s NICE requested more information from AstraZeneca regarding preliminary draft guidance for Lynparza olaparib for maintenance treatment of ovarian, fallopian tube or primary peritoneal cancer. The appraisal committee that developed the guidance asked AZ to provide a “robust” estimate of the cost-effectiveness of Lynparza for patients with relapsed disease who had undergone at least three courses of platinum-based chemotherapy. ...